ArticleAnnals of medicine2026
Homocysteine, cysteine and methionine are associated with 90-day prognosis in intracerebral hemorrhage patients.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis retrospective study explored the associations of plasma homocysteine (Hcy), cysteine (Cys) and methionine (Met) levels with 90-day prognosis in intracerebral hemorrhage (ICH) patients and evaluated their predictive value for ICH prognosis.
methodsA total of 212 ICH patients and 215 age- and sex-matched healthy controls were enrolled. ICH patients were categorized into favorable and unfavorable prognostic groups based on their 90-day prognosis. Plasma Hcy, Cys and Met levels were compared between groups. Multivariate logistic regression and ROC curve analyses were used to assess their prognostic correlations and predictive efficacy. Restricted Cubic Spline (RCS) analysis explored the nonlinear relationship between Met and prognosis. The predictive model was internally validated and compared with classic ICH prognostic scoring systems.
resultsICH patients had significantly higher Hcy, Cys and Met levels than healthy controls. Unfavorable prognosis patients presented higher Hcy and Cys levels but lower Met levels. High Hcy (OR = 1.235, 95%CI 1.137-1.342) and Cys (OR = 1.017, 95%CI 1.008-1.025) were independent risk factors for poor prognosis. Met exerted a dual nonlinear effect and played a protective role at levels <32.88 μmol/L (OR = 0.924, 95%CI 0.860-0.992). The combined three biomarkers yielded the optimal predictive performance (AUC = 0.819), superior to all single and pairwise biomarker combinations.
conclusionElevated Hcy, Cys and Met levels are observed in ICH patients. High Hcy and Cys predict unfavorable prognosis. Met exhibited concentration-dependent correlational trends, lower odds of adverse outcomes were observed for Met <32.88 μmol/L. Combined detection of the three biomarkers yielded the highest predictive accuracy in internal single-center validation, pending external prospective verification before clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.